ReviewResearch and reports in urology2013
Pharmacotherapy of overactive bladder in adults: a review of efficacy, tolerability, and quality of life.
Review in Research and reports in urology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Overactive bladder - 18 years - Part II.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Overactive bladder medications and risk of emergency hospital admissions with delirium in adults without dementia: self-controlled case series.Age and ageing · 2025Article
- Investigating the Pharmacological Impact of Atosiban, an Oxytocin Receptor Antagonist, on Bladder and Prostate Contractions Within OBESE and Non-Obese Rats.Biomedicines · 2025Article
- Effect of a Peripheral Neuromodulation Protocol Combined with the Application of Therapeutic Exercise in Patients Diagnosed with Urinary Incontinence-A Study Protocol for a Randomized Controlled Trial.Healthcare (Basel, Switzerland) · 2025Article
- Age-Dependent Effects of Oxytocin and Oxytocin Receptor Antagonists on Bladder Contractions: Implications for the Treatment of Overactive Bladder Syndrome.Biomedicines · 2024Article
- Flat Magnetic Stimulation for Urge Urinary Incontinence.Medicina (Kaunas, Lithuania) · 2023Article
- Article
- Functional Polymorphism in theJournal of clinical medicine · 2022Article
- URINARY INCONTINENCE - FROM CHILDHOOD ONWARDS.Acta clinica Croatica · 2022Review
- Learning Curve of Botulinum Toxin Bladder Injection for the Treatment of Refractory Overactive Bladder.International journal of women's health · 2022Article
- Intravesical injection of onabotulinumtoxinA in neurogenic overactive bladder patients with human T-cell leukemia virus type 1-associated myelopathy: A single-institution case series.IJU case reports · 2021Article
- Prevalence of overactive bladder in China, Taiwan and South Korea: Results from a cross-sectional, population-based study.Lower urinary tract symptoms · 2019Article
- What Is the Role of Additional Pharmacotherapy and Neuromodulation in Patients with Marginal Benefit from Botulinum Toxin Injection?Current urology reports · 2018Review
- Comparison of Oxidative Effects of Two Different Administration Form of Oxybutynin in the Potential Target Tissues.Advances in urology · 2018Article
- Radiographic Position of the Electrode as a Predictor of the Outcome of InterStim Therapy.International neurourology journal · 2017Article
- Premature contractions of the bladder are suppressed by interactions between TRPV4 and SK3 channels in murine detrusor PDGFRαScientific reports · 2017Article
- Stimulation of the pelvic nerve increases bladder capacity in the prostaglandin EAmerican journal of physiology. Renal physiology · 2017Article
- Optogenetic Modulation of Urinary Bladder Contraction for Lower Urinary Tract Dysfunction.Scientific reports · 2017Article
- New life in overactive bladder. Focus on "Novel regulatory mechanism in human urinary bladder: central role of transient receptor potential melastatin 4 channels in detrusor smooth muscle function".American journal of physiology. Cell physiology · 2016Article
- The efficacy and tolerability of mirabegron, a β3 adrenoceptor agonist, in patients with symptoms of overactive bladder.Therapeutic advances in urology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionOveractive bladder (OAB) is a prevalent condition that has a significant impact on quality of life. The usual treatment approach is both behavioral and pharmacological. The first-line pharmacological treatment commonly utilizes anticholinergic agents, which may be limited by their tolerability, efficacy, and long-term compliance. Developments in elucidating the pathophysiology of OAB and alternative targets for pharmacological therapy have led to newer agents being developed to manage this condition. These agents include mirabegron and botulinum toxin, which have alternate mechanism of action and avoid the anticholinergic side effects.
objectivesTo provide an update for clinicians managing OAB with an overview of the existing and newer medical options for OAB, including pharmacology, efficacy, side-effect profile, tolerability, and impact on patient quality of life.
methodsPubMed and Medline were searched for randomized controlled drug trials in adults with OAB, meta-analyses of medical therapy for OAB, and individual drug names, including the keywords efficacy, tolerability, quality of life, and compliance. Nonhuman studies, pediatric trials, and those involving patients with neurogenic bladder dysfunction (with the exception of studies involving botulinum toxin A) were excluded.
resultsThere is level 1, Grade A evidence to support the efficacy of anticholinergic drugs, botulinum toxin, and mirabegron for OAB. Long-term compliance with anticholinergic medications is limited. The mechanism of action, effectiveness, and side effects of these drugs are discussed, and where the data are available compared with other OAB medications.
conclusionMost of the anticholinergic agents have comparative efficacies and core side-effect profiles, with individual variations relating to their muscarinic receptor selectivity, pharmacokinetics, and metabolism. Newer agents, with alternative sites of action, such as mirabegron and botulinum toxin, provide additional treatment options for patients intolerant to or inadequately treated with anticholinergics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.